Medicare Enrolled

Dr. Lohaliz Bobe, MD

Pulmonary Disease · Port Charlotte, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Low-engagement
4235 KINGS HWY, Port Charlotte, FL 33980
9416131777
In practice since 2009 (16 years)
NPI: 1851528202 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Bobe from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Bobe? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Bobe

Dr. Lohaliz Bobe is a pulmonary disease in Port Charlotte, FL, with 16 years in practice. Based on federal Medicare data, Dr. Bobe performed 6,083 Medicare services across 4,341 unique beneficiaries.

Between the years covered by Open Payments, Dr. Bobe received a total of $18,567 from 56 pharmaceutical and/or device companies across 1002 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Bobe is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 16 years in practice▲ Top 4% volume in FL$ $18,567 industry payments

Medicare Practice Summary

Medicare Utilization ↗
6,083
Medicare services
Top 4% in FL for pulmonary disease
4,341
Unique beneficiaries
$78
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~380 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (30-39 min)1,018$95$163
Hospital follow-up visit, high complexity883$95$140
Critical care, first 30-74 min602$172$339
Test to determine lung volumes using gas dilution or washout415$33$73
Test to examine how well the lungs exchange gases413$42$98
Remote patient monitoring device, 30 days371$37$86
Office visit, established patient (20-29 min)301$60$115
Hospital follow-up visit, moderate complexity277$64$91
Test to measure expiratory airflow and volume237$20$62
Evaluation of use of breathing device205$13$30
Initial hospital admission, high complexity192$132$217
Test to measure expiratory airflow and volume changes before and after medication administration181$29$107
Office visit, established patient, complex (40-54 min)173$128$221
Test to measure oxygen level in blood using ear or finger device continuously overnight158$19$63
Test for exercise-induced lung stress139$25$51
New patient office visit (45-59 min)80$131$250
New patient office visit, complex (60-74 min)79$161$315
Smoking and tobacco use intensive counseling, 4-10 minutes68$15$20
Aspiration of initial secretion of lung airway using an endoscope67$101$332
Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making)56$29$50
Smoking and tobacco use intensive counseling, more than 10 minutes43$28$35
Telephone medical discussion with physician, 21-30 minutes22$94$164
New patient office visit (30-44 min)20$81$163
Irrigation and suction of lung airways to obtain cells using an endoscope18$1$342
Biopsy of lobe of lung using an endoscope, 1 lobe15$73$400
Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 3 or more lymph nodes14$197$500
Emergent insertion of breathing tube into windpipe using an endoscope12$108$200
Office visit, established patient (10-19 min)12$45$70
Telephone medical discussion with physician, 11-20 minutes12$60$113
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$18,567
Total received (2018-2024)
Avg $2,652/year across 7 years
Top 12% in FL for pulmonary disease
56
Companies
1,002
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$18,350 (98.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$217 (1.2%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$3,620
2023
$3,596
2022
$3,052
2021
$2,131
2020
$1,492
2019
$2,405
2018
$2,271

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
GlaxoSmithKline, LLC.
$2,968
AstraZeneca Pharmaceuticals LP
$2,814
Takeda Pharmaceuticals U.S.A., Inc.
$2,310
Actelion Pharmaceuticals US, Inc.
$1,716
Boehringer Ingelheim Pharmaceuticals, Inc.
$931
Regeneron Healthcare Solutions, Inc.
$739
Grifols USA, LLC
$679
Ethicon Inc.
$635
Insmed, Inc.
$628
Mylan Specialty L.P.
$561
GENZYME CORPORATION
$419
Sunovion Pharmaceuticals Inc.
$386
Paratek Pharmaceuticals, Inc.
$324
Bayer HealthCare Pharmaceuticals Inc.
$295
Genentech USA, Inc.
$269
CSL Behring
$232
Novartis Pharmaceuticals Corporation
$225
Bayer Healthcare Pharmaceuticals Inc.
$220
Shire North American Group Inc
$205
United Therapeutics Corporation
$195
Philips Electronics North America Corporation
$169
Amgen Inc.
$155
Circassia Pharmaceuticals Inc
$124
Covidien LP
$120
Electromed, Inc.
$118
Mallinckrodt Hospital Products Inc.
$112
Gilead Sciences, Inc.
$109
ANI Pharmaceuticals, Inc.
$95
Vanda Pharmaceuticals Inc.
$92
Intuitive Surgical, Inc.
$64
Merck Sharp & Dohme LLC
$57
JAZZ PHARMACEUTICALS INC.
$50
Advanced Respiratory, Inc
$44
ABBVIE INC.
$41
Mallinckrodt Enterprises LLC
$33
AbbVie Inc.
$32
Axsome Therapeutics, Inc.
$30
Chiesi USA, Inc.
$28
Ambu Inc.
$26
Kerecis Limited
$26
PORTOLA PHARMACEUTICALS, INC.
$26
BOSTON SCIENTIFIC CORPORATION
$24
Vapotherm Inc
$24
Tactile Systems Technology Inc
$21
PFIZER INC.
$21
Allergan Inc.
$20
La Jolla Pharmaceutical Company
$19
Inogen, Inc.
$19
Janssen Pharmaceuticals, Inc
$18
Boston Scientific Corporation
$18
ADVANCED RESPIRATORY, INC
$18
OptiNose US, Inc.
$15
Veran Medical Technologies, Inc.
$15
Allergan, Inc.
$15
Mallinckrodt LLC
$12
Nabriva Therapeutics, plc
$11
Top 3 companies account for 43.6% of total payments
Associated products mentioned in payments ›
(8874) inCourage · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · AVYCAZ · Adempas · Arikayce · BEVYXXA · BREO · BREZTRI · BREZTRI AEROSPHERE · BROVANA · CLEVIPREX · CUVITRU · DUAKLIR PRESSAIR · DUPIXENT · Da Vinci Surgical System · Dymista · EXPECT · Esbriet · FARXIGA · FASENRA · Flexitouch Plus · GENERAL THROMBECTOMY · GIAPREZA · GLASSIA · HETLIOZ · HYQVIA · INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH · JARDIANCE · Kcentra · Kerecis Omega3 SurgiClose · LONHALA MAGNAIR · Life 2000 Ventilation System · MONARCH · Monarch Platform · NUCALA · NUZYRA · OFEV · OPSUMIT · OPSUMIT MACITENTAN · ORENITRAM · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Perforomist · Precision Flow · Prolastin-C Liquid · SMARTVEST · SPIRIVA RESPIMAT · STIOLTO RESPIMAT · SYMBICORT · Spin · Sunosi · SuperDimension · TEFLARO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · TYVASO · The Vest System Model 105 Home Care · UPTRAVI · UTIBRON NEOHALER · Utibron · WINREVAIR · XOLAIR · XYREM · Xenleta · Xhance · Xolair · YUPELRI · Yupelri · Zemaira · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $305 per 100 Medicare services performed
Looking for a pulmonary disease in Port Charlotte?
Compare pulmonary diseases in the Port Charlotte area by procedure volume, costs, and industry payment transparency.
Browse pulmonary diseases nearby

Geographic Context

Pulmonary Diseases within 10 mi
9
Per 100K population
4.6
County median income
$66,154
Nearest hospital
Adventhealth Port Charlotte
2.9 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Bobe is a clinical cardiology specialist, with above-average Medicare volume (top 4% in FL), and high industry engagement (low-engagement, top 12%), with 16 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Bobe experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Bobe performed 1,018 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Bobe receive payments from pharmaceutical companies?
Yes. Dr. Bobe received a total of $18,567 from 56 companies across 1,002 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Bobe's costs compare to other pulmonary diseases in Port Charlotte?
Dr. Bobe's average Medicare payment per service is $78. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Bobe) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →